Overall survival was significantly longer in the ramucirumab plus paclitaxel group than in the placebo plus paclitaxel group ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @ % CI @-@ -RSB- , hazard ratio @ -LSB- @ % CI @-@ -RSB- ; p = @ ) .